42 Pulmonary Hypertension Clinical Trials in Indianapolis, IN (2026)

Q: How do I join a clinical trial in Indianapolis?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Indianapolis research site will contact you.

Recruiting Pulmonary Hypertension Studies in Indianapolis

NCT04071327Recruiting

Pulmonary Hypertension Association Registry

The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people...

Indianapolis, IN3,000 participantsPulmonary Hypertension Association, Inc.

View Study Details

NCT05656365Recruiting

Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders

Background: Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) is the most common periodic fever syndrome of childhood. Symptoms can include swelling of the glands in the...

Indianapolis, IN1,500 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

NCT07674758Recruiting

Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials

Dystrophin associated heart dysfunction is a leading cause of death in patients with Duchenne and Becker Muscular dystrophy (DMD/BMD) and Duchenne and Becker muscular dystrophy carriers (MDC); however...

Indianapolis, IN1,000 participantsVanderbilt University Medical Center

View Study Details

NCT04503785Recruiting

Esophageal Impedance and Manometry Measurements and Dysphagia Symptom Scoring

Comparison of manometry measurements and EndoFlip Balloon measurements in patients with dysphagia and a known esophageal diagnosis...

Indianapolis, IN1,000 participantsIndiana University

View Study Details

NCT06091865Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Ly...

Indianapolis, INPHASE3904 participantsRegeneron Pharmaceuticals

View Study Details

NCT06911632Recruiting

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk ...

Indianapolis, INNA900 participantsTempus AI

View Study Details

NCT06149286Recruiting

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of canc...

Indianapolis, INPHASE3470 participantsRegeneron Pharmaceuticals

View Study Details

NCT05685238Recruiting

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

This study is looking at how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used to avoid bleeding episodes. Mim8 wo...

Indianapolis, INPHASE3451 participantsNovo Nordisk A/S

View Study Details

NCT05813678Recruiting

A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)

This is a 10-year multi-center, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the e...

Indianapolis, IN450 participantsBioMarin Pharmaceutical

View Study Details

NCT06051409Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kina...

Indianapolis, INPHASE3350 participantsAscentage Pharma Group Inc.

View Study Details

NCT07285655Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3)...

Indianapolis, INPHASE3344 participantsLiquidia Technologies, Inc.

View Study Details

NCT05826535Recruiting

Study of LYL314 in Aggressive Large B-Cell Lymphoma

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 ...

Indianapolis, INPHASE1270 participantsLyell Immunopharma, Inc.

View Study Details

NCT06982235Recruiting

Stone and Laser Therapies Post-Market Study (SALT)

The objective of the SALT Study is to obtain post-market safety and device performance data for Boston Scientific's Stone and BPH study devices used during a diagnostic and/or therapeutic urinary trac...

Indianapolis, IN238 participantsBoston Scientific Corporation

View Study Details

NCT06305234Recruiting

A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)

This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with...

Indianapolis, IN200 participantsBioMarin Pharmaceutical

View Study Details

NCT07217704Recruiting

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically co...

Indianapolis, INPHASE3200 participantsSOFIE

View Study Details

NCT06084936Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len...

Indianapolis, INPHASE3182 participantsHoffmann-La Roche

View Study Details

NCT04177914Recruiting

HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the a...

Indianapolis, INPHASE3176 participantsUniversity of Utah

View Study Details

NCT07488676Recruiting

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the ...

Indianapolis, INPHASE1150 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT07486934Recruiting

Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1)....

Indianapolis, INPHASE3150 participantsDyne Therapeutics

View Study Details

NCT06379789Recruiting

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an ex...

Indianapolis, INPHASE1130 participantsRegeneron Pharmaceuticals

View Study Details

NCT05481879Recruiting

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

The primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study...

Indianapolis, INPHASE1116 participantsDyne Therapeutics

View Study Details

NCT07119268Recruiting

SPARK Healthy Sleep

SPARK-Healthy Sleep is a digital mental health intervention designed to help college students who may be at risk for psychosis and experience sleep problems. About 1 in 4 college students report psych...

Indianapolis, INNA115 participantsIndiana University

View Study Details

NCT05465070Recruiting

Leg Heat Therapy in Peripheral Artery Disease

The goal of this randomized, double-blind, sham-controlled clinical trial is to evaluate the benefits of home-based, leg heat therapy (HT) on lower-extremity functioning and quality of life in patient...

Indianapolis, INNA106 participantsIndiana University

View Study Details

NCT04920617Recruiting

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refr...

Indianapolis, INPHASE2102 participantsImmunoVaccine Technologies, Inc. (IMV Inc.)

View Study Details

NCT05022459Recruiting

Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis

Hemophilia A (HA) is a genetic bleeding disorder resulting from a deficiency or absence of factor VIII (FVIII), which is necessary in the clotting process. This disorder occurs mostly in males and in ...

Indianapolis, IN72 participantsWayne State University

View Study Details

NCT05778188Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left w...

Indianapolis, INPHASE270 participantsReAlta Life Sciences, Inc.

View Study Details

NCT05987449Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter trial consisting of two parts: * Part 1 is a multiple-ascending dose (MAD) study in adult and adolescent male participants wit...

Indianapolis, INPHASE160 participantsHoffmann-La Roche

View Study Details

NCT05465174Recruiting

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma....

Indianapolis, INPHASE257 participantsSabine Mueller, MD, PhD

View Study Details

NCT03681561Recruiting

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose...

Indianapolis, INPHASE154 participantsVeronika Bachanova

View Study Details

NCT05719935Recruiting

The KinematX Midcarpal Total Wrist Arthroplasty Registry

The goal of this observational study is to learn about functional and patient reported outcomes in patient undergoing total wrist replacement with the KinematX total wrist replacement study. The main...

Indianapolis, IN50 participantsExtremity Medical

View Study Details

NCT06165341Recruiting

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Maki...

Indianapolis, INPHASE350 participantsTakeda

View Study Details

NCT07096843Recruiting

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN...

Indianapolis, INPHASE245 participantsClimb Bio, Inc.

View Study Details

NCT05039619Recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less...

Indianapolis, INPHASE240 participantsHoffmann-La Roche

View Study Details

NCT05852717Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Da...

Indianapolis, INPHASE235 participantsDipenkumar Modi

View Study Details

NCT04555161Recruiting

Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System

This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right hea...

Indianapolis, INNA30 participantsAria CV, Inc

View Study Details

NCT07220564Recruiting

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophil...

Indianapolis, INPHASE130 participantsNovo Nordisk A/S

View Study Details

NCT04972942Recruiting

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell trans...

Indianapolis, INPHASE130 participantsNew York Medical College

View Study Details

NCT07024693Recruiting

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy....

Indianapolis, INPHASE228 participantsDesign Therapeutics, Inc.

View Study Details

NCT06525636Recruiting

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

A first-in-human study of KK8123 in adults with X-linked hypophosphatemia....

Indianapolis, INPHASE124 participantsKyowa Kirin Co., Ltd.

View Study Details

NCT06484920Recruiting

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgki...

Indianapolis, INPHASE224 participantsRita Assi

View Study Details

NCT07054684Recruiting

Study of BHV-1400 in IgA Nephropathy

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN)....

Indianapolis, INPHASE120 participantsBiohaven Therapeutics Ltd.

View Study Details

NCT03312686Recruiting

Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study

This pilot study will explore whether treatment of eosinophilic inflammation in the esophagus is associated with an improved distensibility of the esophagus. Furthermore, previous studies of the esoph...

Indianapolis, IN10 participantsIndiana University

View Study Details

About Pulmonary Hypertension Clinical Trials in Indianapolis

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 42 pulmonary hypertension clinical trials recruiting participants in Indianapolis, IN. These studies are seeking a combined 13,233 participants. Research is being sponsored by Pulmonary Hypertension Association, Inc., National Institute of Allergy and Infectious Diseases (NIAID), Vanderbilt University Medical Center and 29 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in Indianapolis — FAQ

Are there pulmonary hypertension clinical trials in Indianapolis?

Yes, there are 42 pulmonary hypertension clinical trials currently recruiting in Indianapolis, IN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Indianapolis?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Indianapolis research site will contact you about next steps.

Are clinical trials in Indianapolis free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Indianapolis studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 42 active trials in Indianapolis are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated July 17, 2026 from ClinicalTrials.gov